Search Clinical Trials in the European Union

3-6 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1-20 of 331 trials

Chronic Pain in Children: Capsaicin Patch Study

We are investigating whether a capsaicin patch can help relieve chronic pain in children aged 12 to 17 after surgery or injury. The study will also look at how well the treatment is tolerated and its effects on other pain medications.

Chronic Neuropathic Pain3-6 monthsConfirmation phase (III)Investigational MedicinesNeurologyPediatrics

Tranexamic Acid for Spontaneous Brain Bleeding

We are studying whether tranexamic acid can help reduce early deaths in patients with spontaneous intracerebral hemorrhage. Additionally, we will look at its effects on recovery six months later.

Stroke3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesNeurology

Ikervis for Atopic Keratoconjunctivitis

We are studying whether Ikervis, applied four times a day, can effectively treat atopic keratoconjunctivitis. This trial aims to see how well it works compared to a placebo.

Atopic Keratoconjunctivitis3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementOphthalmology

Prostate Cancer: Neoadjuvant Treatment with [177Lu]Lu-PSMA-617

We are studying a new method of delivering a targeted treatment for men with high-risk prostate cancer before surgery. The goal is to evaluate its safety and how well it works compared to standard approaches.

High-Risk Prostate Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Episodic Migraine: Atogepant for Kids and Teens

We are studying the safety and effectiveness of Atogepant tablets for children and teens aged 6 to 17 with episodic migraines. This trial compares the medication to a placebo to see if it helps reduce migraine symptoms.

Episodic Migraine3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

HER2-Positive Early Breast Cancer: Inavolisib Study

We are investigating whether adding the drug inavolisib to standard treatments helps patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer achieve better treatment responses. This study compares the new combination therapy to standard therapy alone.

Breast Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Pancreatic Cancer: mFOLFIRINOX with Radiation Therapy

We are studying whether adding high-dose radiation therapy to standard chemotherapy helps patients with borderline resectable pancreatic cancer have better surgical outcomes and survival rates.

Pancreatic Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

COVID-19 Treatment: Antiviral Therapy for Immunocompromised Patients

We are studying a combination of antiviral medications to see if it helps immunocompromised patients recover from COVID-19 more effectively. The goal is to improve viral clearance and reduce symptoms compared to standard treatments.

Covid-193-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Atopic Dermatitis: Lebrikizumab for Kids

We are studying a new treatment for children and teens with moderate-to-severe atopic dermatitis. The goal is to see if it works better than a placebo when used alongside standard treatments.

Atopic Dermatitis (Eczema)3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesDermatology

HER2-positive Breast Cancer: Trastuzumab Deruxtecan Study

We are comparing a new treatment with standard therapy for patients with HER2-positive breast cancer. The goal is to see which approach leads to better outcomes and to understand the effects on quality of life.

HER2 Positive Breast Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Irritable Bowel Syndrome: Ebastine vs. Mebeverine

We are comparing the effectiveness of ebastine and mebeverine for treating irritable bowel syndrome. The study also looks at how these treatments impact quality of life for patients.

Irritable Bowel Syndrome3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesGastroenterologyInternal Medicine

Generalized Myasthenia Gravis: Ravulizumab for Kids

We are studying the effects of Ravulizumab in children with Generalized Myasthenia Gravis to see how well it works and its safety. This trial will help us understand if it improves their quality of life.

Generalized Myasthenia Gravis3-6 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPediatrics

Advanced Dedifferentiated Liposarcoma: Pemigatinib and Retifanlimab Study

We are studying the effects of two medications on patients with advanced dedifferentiated liposarcoma. The goal is to see if they improve treatment outcomes and quality of life.

Dedifferentiated Liposarcoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Myasthenia Gravis: Rozanolixizumab for Kids

We are studying if rozanolixizumab is safe and effective for children with moderate to severe myasthenia gravis. This trial will help us understand how the medication works in young patients.

Myasthenia Gravis3-6 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesNeurologyPediatrics

Osteoporosis: Dasatinib and Quercetin Study

We are investigating whether a combination of dasatinib and quercetin can help improve bone health in patients with low bone mass. This study aims to see if it reduces bone loss more effectively than current treatments.

OsteoporosisOsteopenia3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

Semaglutide for Reducing GI Issues in Chemotherapy Patients

We are studying whether semaglutide can help lessen gastrointestinal problems in patients undergoing high-dose chemotherapy and stem cell transplantation. The trial also looks at its safety and effects on gut health.

Mucositis and Systemic Inflammation3-6 monthsEfficacy phase (II)Standard MedicinesCost ReimbursementGastroenterologyOncology

Chronic Spontaneous Urticaria: Remibrutinib for Teens

We are studying a new medication, remibrutinib, for adolescents with chronic spontaneous urticaria that isn't well controlled by antihistamines. The goal is to see if it can reduce symptoms like hives and itching more effectively than a placebo.

Chronic Spontaneous Urticaria3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesAllergologyDermatology

Atorvastatin for Preventing Episodic Migraines

We are studying whether atorvastatin can help reduce the frequency of episodic migraines in participants. This trial will also look at how well different doses work and any side effects that may occur.

Migraine3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesNeurology

Prostate Cancer: 177Lu-PSMA-617 Treatment Study

We are evaluating whether adding 177Lu-PSMA-617 to standard treatment helps men with metastatic hormone-sensitive prostate cancer who are not responding well to current therapies. The goal is to see if this combination improves survival and disease control.

Hormone-sensitive Metastatic Prostate Cancer3-6 monthsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Thromboprophylaxis for Advanced Germ Cell Tumors

We are studying a preventive treatment for patients with advanced germ cell tumors undergoing chemotherapy to see if it can help reduce the risk of blood clots. The trial also looks at the safety and cost-effectiveness of this treatment.

Testicular Germ Cell Tumor3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology